Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSS | P25774 | 1/20 | 0.45 |
| ▸ | CTSK | P43235 | 1/20 | 0.45 |
| ▸ | GRN | P28799 | 4/20 | 0.44 |
| ▸ | SORT1 | Q99523 | 4/20 | 0.44 |
| ▸ | S1PR3 | Q99500 | 2/20 | 0.43 |
| ▸ | PPARA | Q07869 | 3/20 | 0.42 |
| ▸ | PPARG | P37231 | 2/20 | 0.42 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.40 |
| ▸ | CTSL | P07711 | 1/20 | 0.40 |
| ▸ | ACE | P12821 | 1/20 | 0.39 |
| ▸ | APP | P05067 | 1/20 | 0.38 |
| ▸ | GABRB1 | P18505 | 1/20 | 0.38 |
| ▸ | GABRB2 | P47870 | 1/20 | 0.38 |
| ▸ | ATM | Q13315 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10154463 | 0.92 | CTSS (0.41) | CTSSCTSKGRNSORT1S1PR3 | |
| SCHEMBL12326576 | 0.90 | CTSS (0.41) | CTSSCTSKGRNSORT1S1PR3 | |
| SCHEMBL14551911 | 0.90 | S1PR3 (0.44) | CTSSCTSKGRNSORT1S1PR3 | |
| SCHEMBL14668650 | 0.87 | CTSL (0.42) | CTSSCTSKGRNSORT1S1PR3 | |
| SCHEMBL5576749 | 0.86 | S1PR3 (0.55) | CTSSCTSKS1PR3PPARAPPARG | |
| SCHEMBL219211 | 0.86 | S1PR3 (0.55) | CTSSCTSKS1PR3PPARAPPARG | |
| SCHEMBL30370359 | 0.86 | S1PR3 (0.55) | CTSSCTSKS1PR3PPARAPPARG | |
| SCHEMBL26148553 | 0.86 | S1PR3 (0.55) | CTSSCTSKS1PR3PPARAPPARG | |
| SCHEMBL4277192 | 0.85 | S1PR3 (0.53) | CTSSCTSKS1PR3PPARAPPARG | |
| SCHEMBL4289099 | 0.85 | S1PR3 (0.53) | CTSSCTSKS1PR3PPARAPPARG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2016029146-A1 | SPECIFIC INHIBITORS OF METHIONYL-TRNA SYNTHETASE | UNIVERSITY OF WASHINGTON (US) | 2016-02-25 | — | — | WO | claimed |
| US-10913736-B2 | Specific inhibitors of methionyl-tRNA synthetase | UNIVERSITY OF WASHINGTON (US) | 2021-02-09 | — | — | US | disclosed |
| US-20170275279-A1 | SPECIFIC INHIBITORS OF METHIONYL-TRNA SYNTHETASE | UNIVERSITY OF WASHINGTON | 2017-09-28 | — | — | US | disclosed |
| EP-2350020-B1 | SPIRO-IMIDAZOLONE DERIVATIVES AS GLUCAGON RECEPTOR ANTAGONISTS | MERCK SHARP & DOHME (US) | 2014-08-13 | — | — | EP | disclosed |
| EP-2350020-B1 | SPIRO-IMIDAZOLONE DERIVATIVES AS GLUCAGON RECEPTOR ANTAGONISTS | MERCK SHARP & DOHME (US) | 2014-08-13 | — | — | EP | disclosed |
| US-8633231-B2 | Substituted imidazolones, compositions containing such compounds and methods of use | MERCK SHARP & DOHME CORP. (US) | 2014-01-21 | — | — | US | disclosed |
| US-8633231-B2 | Substituted imidazolones, compositions containing such compounds and methods of use | MERCK SHARP & DOHME CORP. (US) | 2014-01-21 | — | — | US | disclosed |
| US-20130123315-A1 | SUBSTITUTED IMIDAZOLONES, COMPOSITIONS CONTAINING SUCH COMPOUNDS AND METHODS OF USE | MERCK SHARP & DOHME LLC | 2013-05-16 | — | — | US | disclosed |
| US-20130123315-A1 | SUBSTITUTED IMIDAZOLONES, COMPOSITIONS CONTAINING SUCH COMPOUNDS AND METHODS OF USE | MERCK SHARP & DOHME LLC | 2013-05-16 | — | — | US | disclosed |
| US-8361959-B2 | Spiro-imidazolone derivatives as glucagon receptor antagonists | MERCK SHARP & DOHME CORP. (US) | 2013-01-29 | — | — | US | disclosed |
| US-20130012434-A1 | NOVEL SPIRO IMIDAZOLONES AS GLUCAGON RECEPTOR ANTAGONISTS, COMPOSITIONS, AND METHODS FOR THEIR USE | MERCK SHARP & DOHME CORP. | 2013-01-10 | — | — | US | disclosed |
| US-20130012434-A1 | NOVEL SPIRO IMIDAZOLONES AS GLUCAGON RECEPTOR ANTAGONISTS, COMPOSITIONS, AND METHODS FOR THEIR USE | MERCK SHARP & DOHME CORP. | 2013-01-10 | — | — | US | disclosed |
| US-20130012434-A1 | NOVEL SPIRO IMIDAZOLONES AS GLUCAGON RECEPTOR ANTAGONISTS, COMPOSITIONS, AND METHODS FOR THEIR USE | MERCK SHARP & DOHME CORP. | 2013-01-10 | — | — | US | disclosed |
| WO-2012009226-A1 | SUBSTITUTED IMIDAZOLONES, COMPOSITIONS CONTAINING SUCH COMPOUNDS AND METHODS OF USE | MERCK SHARP & DOHME CORP. (US) | 2012-01-19 | — | — | WO | disclosed |
| WO-2011119559-A1 | NOVEL SPIRO IMIDAZOLONES AS GLUCAGON RECEPTOR ANTAGONISTS, COMPOSITIONS, AND METHODS FOR THEIR USE | SCHERING CORPORATION (US) | 2011-09-29 | — | — | WO | disclosed |
| EP-2350020-A1 | SPIRO-IMIDAZOLONE DERIVATIVES AS GLUCAGON RECEPTOR ANTAGONISTS | Schering Corporation (US) | 2011-08-03 | — | — | EP | disclosed |
| US-20110178007-A1 | SPIRO-IMIDAZOLONE DERIVATIVES AS GLUCAGON RECEPTOR ANTAGONISTS | SCHERING CORPORATION | 2011-07-21 | — | — | US | disclosed |
| US-20110178007-A1 | SPIRO-IMIDAZOLONE DERIVATIVES AS GLUCAGON RECEPTOR ANTAGONISTS | SCHERING CORPORATION | 2011-07-21 | — | — | US | disclosed |
| WO-2010039789-A1 | SPIRO-IMIDAZOLONE DERIVATIVES AS GLUCAGON RECEPTOR ANTAGONISTS | SCHERING CORPORATION (US) | 2010-04-08 | — | — | WO | disclosed |
| WO-2010039789-A1 | SPIRO-IMIDAZOLONE DERIVATIVES AS GLUCAGON RECEPTOR ANTAGONISTS | SCHERING CORPORATION (US) | 2010-04-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130123315-A1 | SUBSTITUTED IMIDAZOLONES, COMPOSITIONS CONTAINING SUCH COMPOUNDS AND METHODS OF USE | UGT2B7, CYP3A43, UGT1A7 | CTSS 1465/4885CTSK 686/4885GRN 1954/4885 |
| US-20170275279-A1 | SPECIFIC INHIBITORS OF METHIONYL-TRNA SYNTHETASE | AARS1, MTR, GARS1 | CTSS 1356/4885CTSK 3981/4885GRN 3887/4885 |
| US-20130012434-A1 | NOVEL SPIRO IMIDAZOLONES AS GLUCAGON RECEPTOR ANTAGONISTS, COMPOSITIONS, AND METHODS FOR THEIR USE | GLP1R, GCGR, GIPR | CTSS 3908/4885CTSK 2891/4885GRN 3425/4885 |
| US-10913736-B2 | Specific inhibitors of methionyl-tRNA synthetase | AARS1, MTR, GARS1 | CTSS 1356/4885CTSK 3981/4885GRN 3887/4885 |
| US-20110178007-A1 | SPIRO-IMIDAZOLONE DERIVATIVES AS GLUCAGON RECEPTOR ANTAGONISTS | GLP1R, GCGR, GIPR | CTSS 4045/4885CTSK 2341/4885GRN 2806/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.